Margo Heath‐Chiozzi

Author

Margo Heath‐Chiozzi

Abbott Fund

Also Known As

M E Heath-Chiozzi, M Heath-Chiozzi, Margo E. Heath-Chiozzi, Margo Heath-Chiozzi, Margo Heath‐Chiozzi

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Abbott Fund Celldex Therapeutics (United States)Charité - Universitätsmedizin Berlin Fraunhofer Institute for Translational Medicine and Pharmacology University of Cincinnati

About

Margo Heath‐Chiozzi is an author at Abbott Fund specializing in medicine, pharmacotherapy, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.2K
2	Pharmacology	1	1	638
3	Clinical Genetics	1	1	20
4	Clinical Microbiology	1	1	32
5	Clinical Trials	1	1	541

Margo Heath‐Chiozzi

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Clinical application of pharmacogenetics Brian B. Spear, Margo Heath‐Chiozzi, Jeffrey Huff Trends in Molecular Medicine Pharmacological StudyPharmacologyClinical ApplicationPharmacogenomicsPharmacotherapy	2001	638
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease D. William Cameron, Margo Heath‐Chiozzi, Sven A. Danner, The Lancet Treatment And PreventionClinical TrialsAntiviral TherapyPharmacotherapyHiv	1998	541
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir Dale J. Kempf, Richard A. Rode, Yi Xu, AIDS	1998	224
The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses Martin Markowitz, Mika Vesanen, Klara Tenner‐Racz, The Journal of Infectious Diseases	1999	182
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen Hernán Valdez, Kimberly Y. Smith, Alan Landay, AIDS	2000	152
Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria Dorothea Terhorst‐Molawi, Tomasz Hawro, Eva Grekowitz, Allergy	2022	108
Characterization of Viral Dynamics in Human Immunodeficiency Virus Type 1–Infected Patients Treated with Combination Antiretroviral Therapy: Relationships to Host Factors, Cellular Restoration, and Virologic End Points Hulin Wu, Daniel R. Kuritzkes, Daniel McClernon, The Journal of Infectious Diseases	1999	107
A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection Brigitta U. Mueller, Robert P. Nelson, John W. Sleasman, PEDIATRICS	1998	94
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C Tariq Ahmad, Philip D. Yin, Jeffrey E. Saffitz, Hepatology	2014	84
Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study Diego Alvarado, Marcus Maurer, Richard Gedrich, Allergy	2022	68

Page 1